This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de MorphoSys de 59.1% y 25% por año respectivamente. Se prevé que el BPA crezca en un 78.2% al año. Se espera que la rentabilidad financiera sea de 7.7% en 3 años.

Información clave

59.1%

Tasa de crecimiento de los beneficios

78.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	42.4%
Tasa de crecimiento de los ingresos	25.0%
Rentabilidad financiera futura	7.7%
Cobertura de analistas	Good
Última actualización	05 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Apr 17

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Nov 26

Previsiones de crecimiento de beneficios e ingresos

XTRA:MOR - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	425	-78	-120	-50	5
12/31/2025	322	-140	-236	-201	8
12/31/2024	180	-249	-296	-253	3
3/31/2024	241	-469	-286	-284	N/A
12/31/2023	238	-190	-299	-296	N/A
9/30/2023	223	104	-363	-355	N/A
6/30/2023	255	100	-349	-338	N/A
3/31/2023	261	-61	-321	-306	N/A
12/31/2022	278	-151	-382	-367	N/A
9/30/2022	250	-861	-436	-417	N/A
6/30/2022	195	-851	-606	-588	N/A
3/31/2022	174	-596	-610	-583	N/A
12/31/2021	180	-514	-508	-481	N/A
9/30/2021	163	-150	-423	-393	N/A
6/30/2021	143	-103	-295	-246	N/A
3/31/2021	124	-177	-255	-217	N/A
12/31/2020	328	98	-14	35	N/A
9/30/2020	303	64	26	63	N/A
6/30/2020	293	105	98	113	N/A
3/31/2020	309	153	137	152	N/A
12/31/2019	72	-103	-85	-81	N/A
9/30/2019	71	-96	-68	-64	N/A
6/30/2019	114	-42	-42	-39	N/A
3/31/2019	87	-59	-33	-31	N/A
12/31/2018	76	-56	-35	-33	N/A
9/30/2018	94	-27	-16	-14	N/A
6/30/2018	54	-82	-61	-48	N/A
3/31/2018	58	-74	-68	-55	N/A
12/31/2017	67	-70	N/A	-38	N/A
9/30/2017	52	-84	N/A	-52	N/A
6/30/2017	49	-73	N/A	-59	N/A
3/31/2017	49	-68	N/A	-47	N/A
12/31/2016	50	-60	N/A	-47	N/A
9/30/2016	49	-45	N/A	-48	N/A
6/30/2016	48	-40	N/A	-41	N/A
3/31/2016	48	-33	N/A	-35	N/A
12/31/2015	106	15	N/A	-24	N/A
9/30/2015	111	27	N/A	-15	N/A
6/30/2015	116	33	N/A	-3	N/A
3/31/2015	119	37	N/A	-4	N/A
12/31/2014	64	-3	N/A	-14	N/A
9/30/2014	61	-6	N/A	-15	N/A
6/30/2014	60	-5	N/A	79	N/A
3/31/2014	77	7	N/A	76	N/A
12/31/2013	78	7	N/A	89	N/A
9/30/2013	80	14	N/A	100	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MOR siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MOR siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MOR siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (25% al año) de MOR crezcan más rápidamente que los del mercado German (5.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (25% al año) de MOR crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de MOR sea baja dentro de 3 años (7.7%).

This company listing is no longer active

MorphoSys Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 167%

Consensus EPS estimates upgraded to €3.87 loss, revenue downgraded

Price target increased by 13% to €35.50

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Price target decreased by 8.7% to €31.78

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

Consensus EPS estimates fall by 167%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?

Consensus EPS estimates upgraded to €3.87 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Price target increased by 13% to €35.50

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

MorphoSys AG's (ETR:MOR) 93% Share Price Surge Not Quite Adding Up

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment improves as stock rises 43%

Consensus EPS estimates fall by 12%, revenue upgraded

Price target decreased by 8.7% to €31.78

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 17%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 16%

Morphosys AG Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Price target increased by 8.0% to €31.61

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to €25.94

Consensus EPS estimates upgraded to €6.45 loss

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 12%

Price target increased by 7.3% to €19.64

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 27% to €18.25

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

Price target decreased to €24.05

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Price target decreased to €26.50

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Consensus forecasts updated

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción